Regardless, simply through the demonstrated clearance of
amyloid in human patients this is a big step forward for the field.
Not exact matches
Specifically, rodents genetically modified to express
human amyloid precursor protein (hAPP), which can lead to the debilitating plaques that form
in the brains of Alzheimer's
patients, seem to struggle to find the hidden platform relative to their healthy peers.
Despite encouraging evidence from animal studies that it clears
amyloid from the brain, when it came to clinical improvements
in human patients the drug proved no better than placebo
in two phase III clinical trials.
The good safety profile of Aducanumab
in patients may well be attributed to the antibody's specific capacity to bond with the abnormally folded beta -
amyloid protein fragment as well as the fact that the antibody is of
human origin.
Therapies applying this paradigm to clear β -
amyloid protein (Aβ) plaques and soluble aggregates from
patients with Alzheimer's disease (AD) is an extremely active field of research, with multiple active and passive Aβ vaccines currently
in human clinical trials.
In a human trial that has now lasted a year, this new immunotherapy cleared near all detectable amyloid - β from patients, and the patients showed improvement in the sense that their decline appeared to slow significantl
In a
human trial that has now lasted a year, this new immunotherapy cleared near all detectable
amyloid - β from
patients, and the
patients showed improvement
in the sense that their decline appeared to slow significantl
in the sense that their decline appeared to slow significantly.
Other studies have shown that dogs affected by this syndrome show deposition of
amyloid (a protein)
in their brains
in patterns very similar to the
amyloid plaques found
in the brains of
human Alzheimer's
patients.